No Data
No Data
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
Data Demonstrated the Use of MyoVista wavECGTM for Screening Preoperative Patients for LVDD Can Be RecommendedSouthlake, Texas, March 26, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a
Heart Test Laboratories Third Quarter 2024 Earnings: US$0.031 Loss per Share (Vs US$0.16 Loss in 3Q 2023)
Heart Test Laboratories Reports Q3 Results
Heart Test Laboratories Cash And Cash Equivalents As Of Jan. 31 Were ~$7.1M
Heart Test Laboratories Cash And Cash Equivalents As Of Jan. 31 Were ~$7.1M
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
Southlake, TX, March 14, 2024 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered
HeartSciences' Announces Peer-Reviewed Publication Evaluating Use of MyoVista Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients With Type 2 Diabetes
Data Demonstrated MyoVista AI-ECG model significantly outperformed NT-proBNP and ARIC HF score, the conventional standards of care for Stage B Heart Failure screeningSouthlake, Texas, March 12, 2024
No Data
Trytosaveabit : Yes! Thanks for the share! I’m anxiously waiting to info to come from this! GL
FortuneHunter : Waiting!